Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Generalized anxiety disorder severity scale (GADSS): a preliminary validation study.

Katherine Shear1, Bea Herbeck Belnap, Sati Mazumdar

  • 1School of Social Work, Columbia University, New York, New York 10027, USA. ks2394@columbia.edu

Depression and Anxiety
|January 18, 2006
PubMed
Summary

The Generalized Anxiety Disorder Severity Scale (GADSS) is a reliable tool for assessing generalized anxiety disorder (GAD) severity in primary care. This validated scale helps track treatment effectiveness over time.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial.

The lancet. Diabetes & endocrinology·2026
Same author

Digital cognitive behavioral therapy and peer support for adolescents and young adults with sickle cell disease and chronic pain: study protocol of a parallel, three-arm, randomized controlled trial (PRESENCE).

Trials·2026
Same author

Factors Associated With Initiation of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonists in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the Kidney CHAMP Trial.

Diabetes spectrum : a publication of the American Diabetes Association·2025
Same author

Impact of Neighborhood Factors on Heart Failure Outcomes: Secondary Analysis From the Hopeful Heart Trial.

JACC. Advances·2025
Same author

Adapting depression collaborative care models to increase uptake of computerized cognitive behavioral therapy at the VA: A pilot randomized controlled trial.

General hospital psychiatry·2025
Same author

Field evaluation of Standard Q Filariasis Antigen Test for Lymphatic Filariasis (LF) during a pre-transmission assessment survey in Sierra Leone, 2022.

PLoS neglected tropical diseases·2025

Area of Science:

  • Psychiatry
  • Primary Care Medicine
  • Clinical Psychology

Background:

  • Generalized Anxiety Disorder (GAD) poses a significant challenge in primary care settings.
  • Accurate assessment and monitoring of GAD severity are crucial for effective treatment.
  • Existing assessment tools may not be optimally suited for primary care environments.

Purpose of the Study:

  • To develop and validate a simple, standardized instrument for assessing GAD severity.
  • To provide researchers and clinicians with an efficient tool for telephone-based assessments.
  • To evaluate the psychometric properties of the Generalized Anxiety Disorder Severity Scale (GADSS).

Main Methods:

  • Development of the six-item Generalized Anxiety Disorder Severity Scale (GADSS).

Related Experiment Videos

  • Telephone assessments conducted by independent evaluators on 330 patients with DSM-IV GAD diagnoses.
  • Evaluation of internal consistency, convergent/discriminant validity, and sensitivity to change over 12 months.

    • Main Results:

    • The GADSS demonstrated high internal consistency.
    • The scale exhibited good convergent and discriminant validity.
    • GADSS scores showed significant sensitivity to change and discriminated between treatment strategies.

    Conclusions:

    • The Generalized Anxiety Disorder Severity Scale (GADSS) is a valid and reliable instrument for assessing GAD severity.
    • GADSS provides a simple and efficient method for telephone-based severity ratings in primary care.
    • This tool can aid in monitoring treatment response for patients with GAD.